$74.12
0.52% yesterday
Nasdaq, Feb 04, 10:13 pm CET
ISIN
US45337C1027
Symbol
INCY
Sector
Industry

Incyte Stock price

$74.12
+2.21 3.07% 1M
+12.12 19.55% 6M
+5.05 7.31% YTD
+16.06 27.66% 1Y
+1.43 1.97% 3Y
+0.24 0.32% 5Y
+1.10 1.51% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.38 0.52%
ISIN
US45337C1027
Symbol
INCY
Sector
Industry

Key metrics

Market capitalization $14.28b
Enterprise Value $12.54b
P/E (TTM) P/E ratio 524.93
EV/FCF (TTM) EV/FCF 408.50
EV/Sales (TTM) EV/Sales 3.08
P/S ratio (TTM) P/S ratio 3.50
P/B ratio (TTM) P/B ratio 4.51
Revenue growth (TTM) Revenue growth 12.94%
Revenue (TTM) Revenue $4.08b
EBIT (operating result TTM) EBIT $-12.09m
Free Cash Flow (TTM) Free Cash Flow $30.70m
Cash position $1.77b
EPS (TTM) EPS $0.14
P/E forward 195.71
P/S forward 3.39
EV/Sales forward 2.98
Short interest 4.65%
Show more

Is Incyte a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Incyte Stock Analysis

Unlock Scores for Free

Analyst Opinions

29 Analysts have issued a Incyte forecast:

13x Buy
45%
15x Hold
52%
1x Sell
3%

Analyst Opinions

29 Analysts have issued a Incyte forecast:

Buy
45%
Hold
52%
Sell
3%

Financial data from Incyte

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
4,076 4,076
13% 13%
100%
- Direct Costs 358 358
19% 19%
9%
3,717 3,717
12% 12%
91%
- Selling and Administrative Expenses 1,056 1,056
5% 5%
26%
- Research and Development Expense 2,585 2,585
53% 53%
63%
76 76
88% 88%
2%
- Depreciation and Amortization 88 88
12% 12%
2%
EBIT (Operating Income) EBIT -12 -12
102% 102%
0%
Net Profit 32 32
92% 92%
1%

In millions USD.

Don't miss a Thing! We will send you all news about Incyte directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Incyte Stock News

Neutral
Business Wire
15 days ago
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 8:00 a.m. ET on Monday, February 10, 2025. The schedule for the press release and conference call/webcast is as follows: • Q4 & YE 2024 Press Release: February 10, 2025 at 7:00 a.m. ET • Q4 & YE 2024 Conference Call:...
Neutral
PRNewsWire
20 days ago
– U.S. launch expected in early February – – Niktimvo is the first and only approved treatment for chronic GVHD that targets CSF-1R to reduce the drivers of inflammation and fibrosis – – Pivotal data from the AGAVE-201 trial supporting FDA approval show treatment with Niktimvo resulted in durable responses across all organs studied and patient subgroups – WILMINGTON, Del. and WALTHAM, Mass.
Positive
Seeking Alpha
22 days ago
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions.
More Incyte News

Company Profile

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Head office United States
CEO Herve Hoppenot
Employees 2,524
Founded 1991
Website www.incyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today